SCHEMBL966566

SCHEMBL966566

CCCCNS(=O)(=O)NC(=O)C=Cc1c(C2CC2)nn(C)c1-n1ccc2cc(F)ccc21

nearest known ligand 0.32

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PPARG P37231 1/20 0.32
NPY5R Q15761 1/20 0.32
HCRTR1 O43613 1/20 0.32
HCRTR2 O43614 1/20 0.32
HDAC1 Q13547 2/20 0.31
PLK1 P53350 2/20 0.31
PLK2 Q9NYY3 2/20 0.31
HDAC3 O15379 1/20 0.31
HDAC4 P56524 1/20 0.31
HDAC7 Q8WUI4 1/20 0.31
HDAC2 Q92769 1/20 0.31
HDAC10 Q969S8 1/20 0.31
HDAC11 Q96DB2 1/20 0.31
HDAC8 Q9BY41 1/20 0.31
HDAC6 Q9UBN7 1/20 0.31
HDAC9 Q9UKV0 1/20 0.31
HDAC5 Q9UQL6 1/20 0.31
CCR2 P41597 1/20 0.30
PLK3 Q9H4B4 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL966565 1.00 PPARG (0.32) PPARGNPY5RHCRTR1HCRTR2HDAC1
SCHEMBL966865 0.89 NPY5R (0.41) NPY5RHCRTR1HCRTR2HDAC1PLK1
SCHEMBL966866 0.89 NPY5R (0.41) NPY5RHCRTR1HCRTR2HDAC1PLK1
SCHEMBL966102 0.88 HDAC1 (0.33) HDAC1HDAC3HDAC4HDAC7HDAC2
SCHEMBL966100 0.88 HDAC1 (0.33) HDAC1HDAC3HDAC4HDAC7HDAC2
SCHEMBL964504 0.83 HDAC3 (0.33) HDAC1PLK2HDAC3HDAC4HDAC7
SCHEMBL964506 0.83 HDAC3 (0.33) HDAC1PLK2HDAC3HDAC4HDAC7
SCHEMBL962754 0.82 CNR1 (0.35) HDAC1HDAC3HDAC4HDAC7HDAC2
SCHEMBL962757 0.82 CNR1 (0.35) HDAC1HDAC3HDAC4HDAC7HDAC2
SCHEMBL963819 0.81 PLA2G4A (0.39) NPY5RHCRTR1HCRTR2PLK1PLK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110009384-A1 FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA TAKEDA PHARMACEUTICAL COMPANY LIMITED 2011-01-13 US disclosed
US-20080194617-A1 Fused ring compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-08-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080194617-A1 Fused ring compound SLC5A1, SLC5A2, GPR119 PPARG 248/4885NPY5R 1067/4885HCRTR1 1857/4885
US-20110009384-A1 FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA PPARA, PPARD, PPARG PPARG 3/4885NPY5R 764/4885HCRTR1 1796/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.